| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Luo Peter | 16% | $13,396,141 | 9,175,439 | HAN 2020 Irrevocable Trust | 25 Jan 2025 | |||
| Smith Vincent C | 8.7% | +26% | $9,120,679 | +$2,258,166 | 5,095,351 | +33% | Smith Vincent C | 31 Dec 2025 |
| WuXi PharmaTech Healthcare Fund I L.P. | 7% | -17% | $9,851,138 | -$2,047,783 | 4,121,815 | -17% | WuXi PharmaTech Healthcare Fund I L.P. | 30 Sep 2025 |
| Panacea Innovation Ltd | 3.8% | -28% | $5,377,500 | -$1,882,125 | 2,250,000 | -26% | Panacea Venture Healthcare Fund II, L.P. | 30 Sep 2025 |
| FIL Ltd | 1.8% | -75% | $1,367,743 | -$4,608,764 | 936,810 | -77% | FIL Limited | 31 Mar 2025 |
| FMR LLC | 0.9% | $805,713 | 473,949 | FMR LLC | 30 Jun 2025 |
As of 30 Sep 2025, 17 institutional investors reported holding 5,722,260 shares of Adagene Inc. - Ordinary Shares (ADAG). This represents 9.8% of the company’s total 58,567,256 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 2,880,400 | $5,632,027 | +$2,061,648 | $1.89 | 13 |
| 2025 Q3 | 5,722,260 | $11,251,842 | -$681,939 | $1.99 | 17 |
| 2025 Q2 | 6,066,432 | $11,842,205 | -$2,692,642 | $1.95 | 15 |
| 2025 Q1 | 7,596,934 | $11,574,144 | -$4,448,525 | $1.54 | 13 |
| 2024 Q4 | 10,441,972 | $20,299,608 | +$6,443,398 | $1.99 | 15 |
| 2024 Q3 | 11,157,880 | $25,316,756 | -$140,637 | $2.22 | 13 |
| 2024 Q2 | 11,223,549 | $33,703,166 | -$3,006,649 | $3.06 | 14 |
| 2024 Q1 | 12,297,346 | $34,335,526 | +$14,756,176 | $2.80 | 17 |
| 2023 Q4 | 5,781,239 | $11,163,839 | -$2,286,153 | $1.93 | 10 |
| 2023 Q3 | 4,096,719 | $6,164,993 | -$21,756 | $1.53 | 10 |
| 2023 Q2 | 4,111,294 | $6,016,229 | -$108,765 | $1.48 | 10 |
| 2023 Q1 | 4,186,071 | $6,023,400 | -$44,707 | $1.45 | 11 |
| 2022 Q4 | 4,216,842 | $5,581,186 | -$2,280,688 | $1.32 | 9 |
| 2022 Q3 | 5,940,279 | $7,603,000 | -$2,338,941 | $1.28 | 11 |
| 2022 Q2 | 7,531,358 | $15,421,000 | -$3,922,347 | $2.03 | 15 |
| 2022 Q1 | 8,391,600 | $29,674,000 | -$1,196,195 | $3.56 | 15 |
| 2021 Q4 | 8,373,818 | $67,324,000 | -$5,705,285 | $8.01 | 16 |
| 2021 Q3 | 8,786,888 | $126,610,000 | +$41,051,134 | $14.37 | 19 |
| 2021 Q2 | 5,937,931 | $80,519,000 | -$15,478,598 | $13.56 | 16 |
| 2021 Q1 | 6,435,237 | $115,522,000 | +$115,521,940 | $17.95 | 27 |